Healthcare provider profile · identity verified

Arthur Badillo, MD

Allopathic & Osteopathic Physicians|Internal Medicine · NEWARK, NJ · NPI 1770635484

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Arthur Badillo, MD received $63.24 in general payments during 2025 across 4 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$63.24

4 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$63.24	100.0%	4	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$63.24	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$63.24	4	2025
Source payment records 2025-02-20 · Boehringer Ingelheim Pharmaceuticals, Inc. · $14.58 · Open Payments source 2025-05-29 · Boehringer Ingelheim Pharmaceuticals, Inc. · $16.81 · Open Payments source 2025-08-11 · Boehringer Ingelheim Pharmaceuticals, Inc. · $15.01 · Open Payments source 2025-10-30 · Boehringer Ingelheim Pharmaceuticals, Inc. · $16.84 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	129	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	129	38

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1411	478
Metformin Hcl	Metformin Hcl	858	269
Amlodipine Besylate	Amlodipine Besylate	543	180
Metoprolol Tartrate	Metoprolol Tartrate	510	185
Losartan Potassium	Losartan Potassium	424	140
Enalapril Maleate	Enalapril Maleate	280	88
Alendronate Sodium	Alendronate Sodium	246	92
Pantoprazole Sodium	Pantoprazole Sodium	215	89
Simvastatin	Simvastatin	208	63
Lisinopril	Lisinopril	161	49
Zolpidem Tartrate	Zolpidem Tartrate	154	44
Omeprazole	Omeprazole	146	66
Hydrochlorothiazide	Hydrochlorothiazide	144	47
Hydralazine Hcl	Hydralazine Hcl	139	57
Clopidogrel	Clopidogrel Bisulfate	135	42
Glipizide	Glipizide	132	43
Jardiance	Empagliflozin	129	38
Levothyroxine Sodium	Levothyroxine Sodium	125	38
Tamsulosin Hcl	Tamsulosin Hcl	123	41
Carvedilol	Carvedilol	122	35
Meloxicam	Meloxicam	122	61
Trulicity	Dulaglutide	121	29
Naproxen	Naproxen	120	77
Ibuprofen	Ibuprofen	118	73
Donepezil Hcl	Donepezil Hcl	110	40
Gabapentin	Gabapentin	110	38
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	107	34
Shingrix	Varicella-Zoster Ge/As01b/Pf	107	85
Albuterol Sulfate Hfa	Albuterol Sulfate	103	36
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	95	35
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	93	47
Alcohol Prep Pads	Alcohol Antiseptic Pads	92	19
Furosemide	Furosemide	90	34
Metoprolol Succinate	Metoprolol Succinate	90	39
Januvia	Sitagliptin Phosphate	88	24
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	81	39
Azithromycin	Azithromycin	80	70
Memantine Hcl	Memantine Hcl	77	33
Eliquis	Apixaban	71	19
Fluticasone Propionate	Fluticasone Propionate	71	33
Farxiga	Dapagliflozin Propanediol	62	17
Alprazolam	Alprazolam	61	suppressed
Diclofenac Potassium	Diclofenac Potassium	59	48
Diclofenac Sodium	Diclofenac Sodium	59	26
Clonazepam	Clonazepam	55	25
Rosuvastatin Calcium	Rosuvastatin Calcium	54	18
Meclizine Hcl	Meclizine Hcl	53	22
Tradjenta	Linagliptin	52	12
Glimepiride	Glimepiride	50	12
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	48	37
Betamethasone Dipropionate	Betamethasone Dipropionate	46	27
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	45	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	45	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	44	22
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	36	13
Ramipril	Ramipril	33	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Amoxicillin	Amoxicillin	30	27
Celecoxib	Celecoxib	30	14
Montelukast Sodium	Montelukast Sodium	30	suppressed
Nifedipine Er	Nifedipine	30	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	28	suppressed
Metformin Er Gastric	Metformin Hcl	28	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	28	12
Atenolol	Atenolol	27	suppressed
Glipizide Er	Glipizide	27	suppressed
Nabumetone	Nabumetone	27	20
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	27	suppressed
Indomethacin	Indomethacin	26	13
Tizanidine Hcl	Tizanidine Hcl	25	18
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Sildenafil Citrate	Sildenafil Citrate	23	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	21	suppressed
Latanoprost	Latanoprost	21	suppressed
Levemir Flexpen	Insulin Detemir	21	suppressed
Linzess	Linaclotide	21	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	20	20
Vitamin D2	Ergocalciferol (Vitamin D2)	20	15
Ezetimibe	Ezetimibe	19	suppressed
Valsartan	Valsartan	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Diclofenac Sodium Er	Diclofenac Sodium	18	13
Nitroglycerin	Nitroglycerin	18	13
Ozempic	Semaglutide	18	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	17	15
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Sertraline Hcl	Sertraline Hcl	17	suppressed
Ibu	Ibuprofen	16	11
Hydrocortisone	Hydrocortisone	15	12
Lactulose	Lactulose	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Finasteride	Finasteride	14	suppressed
Temazepam	Temazepam	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Verifine Plus Pen Needle	Pen Needle, Diabetic	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	12
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	13	suppressed
Levocarnitine	Levocarnitine	13	suppressed
Mresvia	Rsv Vaccine, Pref, Mrna/Pf	13	13
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	13	suppressed
Risperidone	Risperidone	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Advocate Pen Needles	Pen Needle, Diabetic	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	12	suppressed
Ammonium Lactate	Ammonium Lactate	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Famotidine	Famotidine	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Levofloxacin	Levofloxacin	12	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	12	11
Prednisone	Prednisone	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$63.24 · 4 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error